Faster radioiodine washout in the treatment of pulmonary metastases of papillary thyroid cancer prepared with recombinant human thyroid-stimulating hormone

Clinical Nuclear Medicine

Volumn 34, Issue 5, 2009, Pages 316-317

  Hung, Guang Uei ^a   Ho, Minglin ^b   Kao, Chia Hung ^c  

^a Chang Bing Show Chwan Hospital   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Metastasis; RhTSH; Thyroid cancer; Thyroid hormone withdrawal

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROXINE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT PROTEIN; THYROID HORMONE; THYROTROPIN;

ADULT; ARTICLE; CASE REPORT; DIAGNOSTIC APPROACH ROUTE; DRUG WITHDRAWAL; FALSE NEGATIVE RESULT; FEMALE; HUMAN; KIDNEY CLEARANCE; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; THYROID HORMONE RELEASE; THYROID HORMONE WITHDRAWAL; THYROID PAPILLARY CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; LUNG TUMOR; METABOLISM; METASTASIS; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; THYROID TUMOR;

ADULT; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; THYROID HORMONES; THYROID NEOPLASMS; THYROTROPIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67849116963     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31819e5108     Document Type: Article

References (9)

1. Serafini AN, Clauss RP, Levis-Dusseau S. Protocol for the combined diagnostic and therapeutic use of recombinant human thyroid-stimulating hormone. Clin Nucl Med. 2003;28:14-17.
2. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926-932.
3. Robbins RJ, Driedger A, Magner J, et al. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid. 2006;16:1121-1130.
4. Jarzab B, Handkiewicz-Junak D, Roskosz J, et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Eur J Nucl Med Mol Imaging. 2003;30:1077-1086.
5. Potzi C, Moameni A, Karanikas G, et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf). 2006;65:519-523.
6. Menzel C, Kranert WT, Döbert N, et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I. J Nucl Med. 2003;44:1065-1068.
7. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2002; 87:4063-4068.
8. Löffler M, Weckesser M, Franzius C, et al. Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma. Nuklearmedizin. 2003;42: 240-243.
9. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in l-thyroxine in the outcome of ablation. J Clin Endocrinol Metab. 2003;88:4110-4115.